Holen Sie sich die Stockscreener-App
45.94
0.48%
0.22
Handel nachbörslich:
46.35
0.41
+0.89%
Schlusskurs vom Vortag:
$45.72
Offen:
$46.2
24-Stunden-Volumen:
6.05M
Relative Volume:
0.73
Marktkapitalisierung:
$18.22B
Einnahmen:
$1.94B
Nettoeinkommen (Verlust:
$-2.82B
KGV:
-6.3263
EPS:
-7.2617
Netto-Cashflow:
$-2.08B
1W Leistung:
-13.07%
1M Leistung:
-9.57%
6M Leistung:
+69.15%
1J Leistung:
+60.97%
1-Tages-Spanne:
$45.75
$47.94
1-Wochen-Bereich:
$44.62
$53.49
52-Wochen-Spanne:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
45.94 | 18.70B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna (MRNA) Prepares for Earnings Amid Revenue Challenges - GuruFocus
Moderna Q1 preview: revenue rebound in focus as losses persist (MRNA:NASDAQ) - Seeking Alpha
Vanguard Capital Management (MRNA) reports 25.9M-share stake (6.53%) - Stock Titan
Moderna in the spotlight: Can pipeline offset earnings decline? By Investing.com - Investing.com Australia
How Will Moderna Stock React To Its Upcoming Earnings? - Trefis
Moderna Stock 5-Day Losing Spree: Stock Falls 18% - Trefis
Discipline and Rules-Based Execution in MRNA Response - Stock Traders Daily
mRNA Treatment Market 2026 | Argos Therapeutics, Inc., CureVac AG, ethris GmbH, Moderna, Inc., Tiba Biotech etc. - openPR.com
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 - Yahoo Finance
Leading Companies Fueling Growth and Innovation in the Spikevax Market - openPR.com
Research Analysts Issue Forecasts for Moderna Q1 Earnings - MarketBeat
Salesforce Says Moderna Selects Agentforce Platform to Consolidate Commercial Operations - Moomoo
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Yahoo Finance
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal? - Yahoo Finance
Moderna Hit With Suit Over CureVac COVID Patents - Law360
Moderna wins full FDA approval for COVID shot in children - MSN
CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots - Bloomberg Law News
Moderna shares dip amid rising selling pressure - Traders Union
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN? - The Motley Fool
Moderna, Inc. (MRNA) Stock Analysis: Navigating A 52-Week High Amidst Revenue Decline - DirectorsTalk Interviews
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $4.12 Million Position in Moderna, Inc. $MRNA - MarketBeat
M&T Bank Corp Acquires 240,400 Shares of Moderna, Inc. $MRNA - MarketBeat
MRNA Price Today: Moderna, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Eagle-Tribune
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - Cadillac News
CureVac sues Moderna over mRNA vaccine patents - Investing.com
Moderna shares slide as traders digest recent EU vaccine clearance and refocus on funding/earnings overhangs - Quiver Quantitative
CureVac sues Moderna over mRNA vaccine patents By Investing.com - Investing.com Canada
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
MRNA Technical Analysis | Trend, Signals & Chart Patterns | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna (MRNA) Expected to Announce Earnings on Friday - MarketBeat
Moderna, Inc. (MRNA) Presents at ESCMID Global 2026Slideshow (NASDAQ:MRNA) 2026-04-23 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
What does smart money think about Moderna (MRNA) stock (+1.11%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - Healthcare Dive
European Commission Approves MRNA's COVID-19-Influenza Combo Shot - Yahoo Finance
Moderna starts late-stage trial for bird flu vaccine - Seeking Alpha
Analyst recommendations: Meta, Amazon, Booking, Goldman Sachs, Moderna… - marketscreener.com
Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines) - marketscreener.com
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot - BioSpace
Moderna Inc. stock (US60770K1034): Does its mRNA pivot beyond COVID now unlock sustainable growth? - AD HOC NEWS
Moderna Inc. (MRNA)Announces Accepted Oncology Clinical Data Presentations at 2026 ASCO Annual Meeting, Schedules Concurrent Investor WebcastFloat Short - UBND thành phố Hải Phòng
Moderna Inc. (MRNA) Secures European Commission Marketing Authorization for World’s First Combined Influenza-COVID mRNA Vaccine mCOMBRIAXCost Structure - UBND thành phố Hải Phòng
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine - GuruFocus
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):